دورية أكاديمية

Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.

التفاصيل البيبلوغرافية
العنوان: Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.
المؤلفون: Gaspar, H Bobby1,2, Parsley, Kathryn L.1, Howe, Steven1, King, Doug1, Gilmour, Kimberly C1,2, Sinclair, Joanna1, Brouns, Gaby1, Schmidt, Manfred3, Von Kalle, Christof3,4, Barington, Torben5, Jakobsen, Marianne A5, Christensen, Hans O6, Al Ghonaium, Abdulaziz7, White, Harry N1, Smith, John L8, Levinsky, Roland J1, Ali, Robin R1,9, Kinnon, Christine1, Thrasher, Adrian J1,2 a.thrasher@ich.ucl.ac.uk
المصدر: Lancet. 12/18/2004, Vol. 364 Issue 9452, p2181-2187. 7p. 1 Black and White Photograph, 2 Charts, 14 Graphs.
مصطلحات موضوعية: *IMMUNODEFICIENCY, *BONE marrow transplantation, *T cells, *GENE therapy, *CYTOKINES, *THERAPEUTICS
مستخلص: Summary Background X-linked severe combined immunodeficiency (SCID-X1) is caused by mutations in the common cytokine-receptor ϒ chain (ϒc), resulting in disruption of development of T lymphocytes and natural-killer cells. B-lymphocyte function is also intrinsically compromised. Allogeneic bone-marrow transplantation is successful if HLA-matched family donors are available, but HLA-mismatched procedures are associated with substantial morbidity and mortality. We investigated the application of somatic gene therapy by use of a gibbon-ape-leukaemia-virus pseudotyped gammaretroviral vector. Methods Four children with SCID-X1 were enrolled. Autologous CD34-positive haemopoietic bone-marrow stem cells were transduced ex vivo and returned to the patients without preceding cytoreductive chemotherapy.The patients were monitored for integration and expression of the ϒc vector and for functional immunological recovery. Findings All patients have shown substantial improvements in clinical and immunological features,and prophylactic medication could be withdrawn in two. No serious adverse events have been recorded. T cells responded normally to mitogenic and antigenic stimuli, and the T-cell-receptor (TCR) repertoire was highly diverse. Where assessable, humoral immunity, in terms of antibody production, was also restored and associated with increasing rates of somatic mutation in immunoglobulin genes. Interpretation Gene therapy for SCID-X1 is a highly effective strategy for restoration of functional cellular and humoral immunity. [ABSTRACT FROM AUTHOR]
قاعدة البيانات: Academic Search Index
الوصف
تدمد:01406736
DOI:10.1016/S0140-6736(04)17590-9